![](https://www.microbiometimes.com/wp-content/uploads/2023/04/shutterstock_410689420-326x245.jpg)
FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that the U.S. Food and […]